



**Figure S2. Schematic diagram of the experimental design for the mouse model of allergic asthma.** To establish the OVA-induced respiratory disease model, mice received intraperitoneal injections of 200 µL OVA solution (10 µg/mouse in PBS with 2 mg Al(OH)<sub>3</sub>) on days 1 and 14. They were then exposed to 3% OVA via intranasal inhalation on days 21-23. SNM complex (50, 100, or 200 mg/kg) or MTK (30 mg/kg) were suspended in sterilized water (vehicle) and administered orally by gavage once daily at 5 mL/kg from day 9 to day 23. All mice were sacrificed on day 24. SNM: a combination of extracts from *Scutellaria baicalensis* (SB), *Nelumbinis semen* (NS), and *Mori cortex* (MC); I.P.: intraperitoneal; I.N.: intranasal; MTK: montelukast.